Does Cigna Cover Zepbound? Express Scripts, Step Therapy, and Working Around the Bottlenecks

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• Cigna covers Zepbound on its commercial formulary at Tier 3 with prior authorization through Express Scripts, its pharmacy benefit manager
• The defining feature of Cigna's process is aggressive step therapy: most plans require a Wegovy or Saxenda trial first
• Step-therapy exceptions are available under federal law and must be answered within 72 hours
• Cigna employer plans frequently include AOM carve-outs that no clinical appeal can overcome
• The realistic fallback paths are Lilly Direct ($499/mo self-pay), brand Wegovy if covered, or compounded tirzepatide

Direct answer

Cigna covers Zepbound on its standard commercial formulary at Tier 3, with prior authorization administered through Express Scripts. As of May 2026, confirm directly with your plan. The single most common Cigna-specific barrier is step therapy: many plans require a 3-month trial of Wegovy or Saxenda before approving Zepbound. Patients can request a step-therapy exception if they have a contraindication, prior treatment failure, or expected adverse interaction with the required step drug. Cigna must respond within 72 hours under federal step-therapy rules.

Table of contents

1. How Cigna and Express Scripts share the work
2. The step-therapy sequence: what Cigna requires before Zepbound
3. Step-therapy exceptions: the rule most patients don't know exists
4. Prior authorization criteria in detail
5. Why employer carve-outs override everything else
6. Costs across coverage tiers
7. The OSA indication and what it changes for Cigna patients
8. What to do when a formulary change happens mid-year
9. Cigna Medicare specifics
10. FAQ
11. Sources

How Cigna and Express Scripts share the work

Cigna's pharmacy benefits are administered by Express Scripts, a sister company under the Cigna Group umbrella since the 2018 acquisition. When you submit a Zepbound prior authorization through Cigna, the actual decision happens at Express Scripts. The clinical criteria, the appeal process, and the formulary updates all run through that PBM.

What this means in practice: when you call Cigna member services about a Zepbound denial, you may be transferred to Express Scripts. The denial letter arrives on Express Scripts letterhead even though your insurance card says Cigna. Provider portals (CoverMyMeds, Surescripts) route Cigna PAs to the Express Scripts queue.

The reason this matters: appeal letters should be addressed to Express Scripts Clinical Review, not to Cigna's medical director's office. Sending to the wrong address adds days to your turnaround.

The step-therapy sequence: what Cigna requires before Zepbound

Cigna's standard commercial step-therapy protocol for Zepbound (2026 edition):

Step	Required drug	Trial duration	Success criteria to advance
1	Phentermine or Saxenda (varies by plan)	3 months	Inadequate response (less than 5% weight loss) or documented intolerance
2	Wegovy (semaglutide)	3 months at maintenance dose	Inadequate response or intolerance
3	Zepbound approved	-	-

The Wegovy step is the most contentious. Cigna's logic is that Wegovy and Zepbound treat the same indication and Wegovy is on a less expensive contract. The clinical counterargument is that head-to-head SURMOUNT vs STEP trial data shows tirzepatide produces greater weight loss (22.5% vs 14.9% at maximum doses), and the SURPASS-2 trial directly compared tirzepatide vs semaglutide in T2D with tirzepatide superiority.

Patients who have already failed Wegovy can usually clear step 2 with documentation. Patients starting from scratch face a real 3-month delay unless they pursue an exception.

Step-therapy exceptions: the rule most patients don't know exists

Federal regulations require commercial insurers and Medicare Advantage plans to offer step-therapy exceptions. Cigna must respond to an exception request within 72 hours (24 hours for urgent cases). Approval requires the prescriber to document one of the following:

• The required step drug is contraindicated for this patient
• The patient has previously tried the step drug and discontinued due to inadequate response or adverse effects
• The required step drug is expected to be ineffective based on patient-specific characteristics
• The required step drug is expected to cause adverse reactions

The most successful exception arguments cite prior semaglutide trials that resulted in GI intolerance. A patient who tried Ozempic at any dose and discontinued has documented standing to skip the Wegovy step. Cigna does not require that the prior trial was paid by Cigna; outside trials count.

Submit the exception with the PA, not after a denial. This collapses two review cycles into one.

Prior authorization criteria in detail

Cigna's Zepbound PA criteria via Express Scripts (current as of May 2026):

• BMI ≥ 30, or BMI ≥ 27 with at least one obesity-related comorbidity
• Age ≥ 18
• Documented prior weight-management intervention (typically 6 months of lifestyle modification)
• Step therapy completed or exception granted
• Prescriber attestation of intent to combine with continued lifestyle counseling
• No concurrent use of another GLP-1 receptor agonist
• Reauthorization at 6 months requires documented weight loss of at least 5% from baseline

The 5% reauthorization threshold is plan-specific. Some Cigna plans require 5% at 4 months; others 7.5% at 12 months. Confirm before the first refill so the prescriber documents the baseline weight properly.

Why employer carve-outs override everything else

Cigna sells administrative services to self-funded employers who can carve out drug categories. AOM exclusions are common in Cigna's employer book of business for the same reason they appear with other carriers: GLP-1 costs are concentrated, predictable, and growing fast.

The 2024 PwC Health Research Institute estimate placed GLP-1 spend at 6-9% of total pharmacy benefit costs for employers offering AOM coverage. Self-funded employers facing budget pressure pull AOM coverage first.

If your plan booklet (the summary plan description, or SPD) lists "weight loss drugs" or "anti-obesity medications" under exclusions, no PA, appeal, or step-therapy exception will produce coverage. The path forward is benefits-level: ask HR for a change at next renewal, or move to self-pay options.

Costs across coverage tiers

Coverage scenario	Monthly OOP	Notes
Cigna approves with Tier 3 fixed copay	$40-$80	Typical commercial plan with stable copay structure
Cigna approves with deductible not met	$1,086 until deductible	Full retail until annual deductible satisfied
Cigna approves with savings card stack	$25	Lilly savings card caps eligible commercial copays
Cigna denies - Lilly Direct vials	$499	Self-pay program through LillyDirect.com
Cigna denies - compounded tirzepatide	$199-$399	503A pharmacy, not FDA-approved
Cigna denies - retail cash	~$1,086	Without manufacturer programs

The OSA indication and what it changes for Cigna patients

The December 2024 FDA approval of Zepbound for obstructive sleep apnea opens a coverage path that bypasses some AOM exclusions. Cigna's commercial plans began updating OSA coverage rules in Q1 2025.

For Cigna patients with OSA:

• The PA still routes through Express Scripts, but the criteria shift
• Requirements: BMI ≥ 30, AHI ≥ 15 on sleep study, ICD-10 G47.33, prescriber documentation
• Step therapy may still apply (CPAP trial typically required first; some plans accept CPAP intolerance documentation)
• Coverage under the OSA benefit category, not AOM, so employer AOM carve-outs may not block it

Cite the SURMOUNT-OSA trial (Malhotra et al. 2024, NEJM) in the prior authorization: tirzepatide reduced AHI by approximately 25 events/hour vs 5 events/hour with placebo, a clinically and statistically significant improvement.

What to do when a formulary change happens mid-year

Cigna and Express Scripts update formularies twice a year (January and July typically). Mid-year changes are allowed for safety, pricing, or generic-availability reasons. Zepbound has been moved between tiers and added to step therapy mid-cycle in multiple Cigna plans during 2024 and 2025.

If your plan changes mid-year:

1. You are entitled to a transition supply (typically 30 days) at the old terms
2. You can file a continuity-of-care exception if you've been stable on Zepbound
3. The exception requires prescriber documentation of clinical stability and risk of regimen disruption
4. If denied, you can appeal externally through your state insurance commissioner

Cigna Medicare specifics

Cigna Medicare Advantage prescription drug plans follow CMS Part D rules. Standard Medicare statute prohibits Part D coverage of weight-loss medications. The 2024 OSA approval created an exception path that some Cigna Medicare plans have adopted.

For Cigna Medicare members seeking Zepbound:

• Weight-loss prescription: not covered
• OSA prescription with documented sleep study: covered on some plans, subject to PA and step therapy with CPAP
• T2D prescription: covered as Mounjaro, not Zepbound (different label, different drug code)

Contrary view: when step therapy actually helps the patient

Step therapy gets a bad reputation in patient communities, and often deservedly so. But there are cases where the protocol benefits patients.

Wegovy (semaglutide) has a different side-effect profile than tirzepatide. A patient who has not tried semaglutide does not know which molecule they tolerate better. Some patients have less GI distress on semaglutide; others have less on tirzepatide. Starting with semaglutide gives the clinician comparison data.

Cost-wise, Wegovy is often cheaper at the cash-pay level than Zepbound. A patient who responds well to Wegovy may not need Zepbound at all.

The legitimate complaint about Cigna's step therapy is not the existence of the protocol but its application without flexibility. Patients who have already failed semaglutide elsewhere should not have to repeat the trial. The exception process exists for that reason; use it.

Decision framework

Submitting a Cigna PA for the first time: Have the prescriber include both the PA and a step-therapy exception request in the same submission if you have any prior GLP-1 history.

Denied for step therapy: File the exception with documentation of prior trial or contraindication. Cigna must respond within 72 hours.

Denied for AOM exclusion: Check whether an OSA pathway is available. If not, move to Lilly Direct or compounded tirzepatide.

Mid-year formulary change: Request continuity-of-care exception within the transition window.

FAQ

Does Cigna cover Zepbound? On the standard commercial formulary, yes, at Tier 3 with PA through Express Scripts. Employer carve-outs and step-therapy requirements affect actual access.

What is the step therapy? Most Cigna plans require Wegovy or Saxenda trial for 3 months before Zepbound approval. Some require phentermine first.

Can I skip step therapy? Yes, with a formal step-therapy exception. Federal law requires Cigna to respond within 72 hours.

How much does Zepbound cost with Cigna? $40-$80 monthly copay typically; $25 with the Lilly savings card on eligible plans.

What if Cigna denies the PA? Read the reason code. Step-therapy denials are appealable; AOM exclusions usually are not.

Does Cigna cover Zepbound for OSA? Yes, on plans that have updated OSA criteria. Requires sleep-study documentation showing AHI ≥ 15.

Does Cigna Medicare cover Zepbound? Not for weight loss. Some plans cover for OSA after the 2024 FDA approval.

How long does Cigna take to decide a PA? 24 to 72 hours after Express Scripts receives complete submission.

Can I use the Lilly savings card with Cigna? Yes, when the plan covers Zepbound. The card cannot bypass an AOM exclusion.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM. 2021.
4. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. NEJM. 2024.
5. FDA. Zepbound prescribing information. Updated 2024.
6. Cigna Pharmacy Drug List. Standard commercial formulary. 2026 edition.
7. Express Scripts. Clinical formulary management policy. 2026.
8. CMS. Part D Drug Coverage Determinations. Updated 2025.
9. NCQA. Step-therapy protocol standards for accreditation. 2024.
10. PwC Health Research Institute. Behind the Numbers: Health Plan Spend Drivers. 2024.
11. Eli Lilly. LillyDirect program for Zepbound self-pay. Accessed May 2026.
12. The Obesity Society. Step-therapy access barriers to AOMs. Position statement 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is not an insurance plan, claims administrator, or pharmacy benefit manager. We connect patients with independent licensed clinicians and pharmacies. Insurance interpretations in this article are educational and should be verified directly with your plan.

Compounded Medication Notice. Compounded tirzepatide is not FDA-approved and is prepared by a state-licensed 503A pharmacy under an individual prescription. It is not therapeutically equivalent to Zepbound and is not covered by Cigna or other commercial insurers.

Results Disclaimer. Coverage examples, cost ranges, and PA outcomes shown here are illustrative. Your plan's specific benefit design, deductible, copay tiers, and step-therapy rules will produce different individual results.

Trademark Notice. Zepbound is a registered trademark of Eli Lilly and Company. Cigna and Express Scripts are registered trademarks of The Cigna Group. Wegovy is a registered trademark of Novo Nordisk. Saxenda is a registered trademark of Novo Nordisk. FormBlends is independent and not affiliated with Cigna, Express Scripts, Eli Lilly, or Novo Nordisk.